p15Ink4b Loss of Expression by Promoter Hypermethylation Adds to Leukemogenesis and Confers a Poor Prognosis in Acute Promyelocytic Leukemia Patients
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose The p15Ink4b gene exerts its influence as an inhibitor of cyclin-dependent kinases and is frequently associated with hematological malignancies. Inactivation of this gene through DNA methylation has been found to be the most prevalent epigenetic alteration reported, with a high frequency in all French-American-British subtypes of acute myeloid leukemias, including acute promyelocytic leukemia (APL). In this study, we investigated the prognostic significance of p15 gene promoter hypermethylation and its expression in APL patients of Kashmir (North India). Materials and Methods p15 gene promoter hypermethylation was conducted by methylation-specific polymerase chain reaction, while its subsequent expression analysis was carried out by semi-quantitative reverse transcriptase polymerase chain reaction (RT-PCR). Results Of the 37 patients, 16 (43.2%) were found to have methylated p15 genes. Of these 16 cases, seven (43.8%) were methylated partially and nine (56.2%) were found to have complete methylation. Moreover, nine of the 37 patients (24.3%) who presented with leukocytosis at their baseline had complete p15 gene methylation as well (p < 0.05). Semiquantitative RT-PCR showed a complete loss of p15 expression in nine patients with complete methylation coupled with leukocytosis (p=0.031), while seven patients with partial methylation showed decreased p15 expression. Six patients relapsed during the maintenance phase of treatment and were found to have a completely methylated p15 gene and no p15 mRNA. Conclusion Complete methylation and loss of p15 gene expression causes susceptibility to relapse and decreased survival in APL patients. Thus, p15 promoter hypermethylation is a prospective prognostic indicator and a reliable clinical aid in assessment of patients with APL.
Abstract
Purpose The p15Ink4b gene exerts its influence as an inhibitor of cyclin-dependent kinases and is frequently associated with hematological malignancies. Inactivation of this gene through DNA methylation has been found to be the most prevalent epigenetic alteration reported, with a high frequency in all French-American-British subtypes of acute myeloid leukemias, including acute promyelocytic leukemia (APL). In this study, we investigated the prognostic significance of p15 gene promoter hypermethylation and its expression in APL patients of Kashmir (North India). Materials and Methods p15 gene promoter hypermethylation was conducted by methylation-specific polymerase chain reaction, while its subsequent expression analysis was carried out by semi-quantitative reverse transcriptase polymerase chain reaction (RT-PCR). Results Of the 37 patients, 16 (43.2%) were found to have methylated p15 genes. Of these 16 cases, seven (43.8%) were methylated partially and nine (56.2%) were found to have complete methylation. Moreover, nine of the 37 patients (24.3%) who presented with leukocytosis at their baseline had complete p15 gene methylation as well (p < 0.05). Semiquantitative RT-PCR showed a complete loss of p15 expression in nine patients with complete methylation coupled with leukocytosis (p=0.031), while seven patients with partial methylation showed decreased p15 expression. Six patients relapsed during the maintenance phase of treatment and were found to have a completely methylated p15 gene and no p15 mRNA. Conclusion Complete methylation and loss of p15 gene expression causes susceptibility to relapse and decreased survival in APL patients. Thus, p15 promoter hypermethylation is a prospective prognostic indicator and a reliable clinical aid in assessment of patients with APL.
참고문헌 (22)
- Di Croce L, "Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor", Science, 295, pp.1079~1082 (2002)
- Nobori T, "Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers", Nature, 368, pp.753~756 (1994)
- Teofili L, "Expression of p15(ink4b)gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors", Blood, 98, pp.495~497 (2001)
- Bergh G, "Involvement of the retinoblastoma protein in monocytic and neutrophilic lineage commitment of human bone marrow progenitor cells", Blood, 94, pp.1971~1978 (1999)
- Haviernik P, "Consistent inactivation of p19(Arf)but not p15(Ink4b)in murine myeloid cells transformed in vivo by deregulated c-Myc", Oncogene, 22, pp.1600~1610 (2003)
- Teofili L, "Expression of cyclin-dependent kinase inhibitor p15(INK4B)during normal and leukemic myeloid differentiation", Exp Hematol, 28, pp.519~526 (2000)
- Aggerholm A, "Extensive intra-and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia", Cancer Res, 59, pp.436~441 (1999)
- Rush LJ, "Alterations of DNA methylation in hematologic malignancies", Cancer Lett, 185, pp.1~12 (2002)
- Bennett JM, "Proposed revised criteria for the classification of acute myeloid leukemia : a report of the French-American-British Cooperative Group", Ann Intern Med, 103, pp.620~625 (1985)
- Chim CS, "Epigenetic inactivation of INK4", CDK, Ann Hematol, pp.2003, 82[DOI]
- Drexler HG, "Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells", Leukemia, 12, pp.845~859 (1998)
- Herman JG, "Hypermethylationassociated inactivation indicates a tumor suppressor role for p15INK4B", Cancer Res, 56, pp.722~727 (1996)
- Issa JP, "DNA methylation changes in hematologic malignancies: biologic and clinical implications", Leukemia, 11(Suppl 1), pp.S7~S11 (1997)
- Teofili L, "Hypermethylation of GpG islands in the promoter region of p15(INK4b)in acute promyelocytic leukemia represses p15(INK4b)expression and correlates with poor prognosis", Leukemia, 17, pp.919~924 (2003)
- Chim CS, "Aberrant gene promoter methylation in acute promyelocytic leukaemia : profile and prognostic significance", Br J Haematol, 122, pp.571~578 (2003)
- Vardiman JW, "The World Health Organization(WHO)classification of the myeloid neoplasms", Blood, 100, pp.2292~2302 (2002)
- Trost D, "Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia", Cancer Genet Cytogenet, 165, pp.51~63 (2006)
- Asou N, "Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group", J Clin Oncol, 16, pp.78~85 (1998)
- Ferrara F, "CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy", J Clin Oncol, 18, pp.1295~1300 (2000)
- Preisler HD, "P15INK4B gene methylation and expression in normal, myelodysplastic, and acute myelogenous leukemia cells and in the marrow cells of cured lymphoma patients", Leukemia, 15, pp.1589~1595 (2001)
- Shimamoto T, "Methylation of p15(INK4b)and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia", Leuk Res, 29, pp.653~659 (2005)
- Deneberg S, "Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia", Leukemia, 24, pp.932~941 (2010)